Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Senisca","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"SENISCA Awarded Innovate UK Grant to Develop Oligonucleotide Therapeutics for The Treatment of Idiopathic Pulmonary Fibrosis (IPF).","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Senisca","sponsor":"Emerging Longevity Ventures","pharmaFlowCategory":"D","amount":"$4.7 million","upfrontCash":"Undisclosed","newsHeadline":"Senisca Secures Additional \u00a33.7 Million Financing to Support Rapid Development of Senotherapeutic Platform to Treat Age-Related Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Senisca

    Menu

    Senisca

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Senisca

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Senisca Secures Additional £3.7 Million Financing to Support Rapid Development of Senotherapeutic Platform to Treat Age-Related Disease

              Details:

              The net proceeds will support the preclinical development of the Company’s senotherapeutic programmes, that target the causes of age-related disease via RNA splicing regulation, resulting in cellular reprogramming and disease modification by attenuating senescence.

              Lead Product(s): Senotherapy

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Emerging Longevity Ventures

              Deal Size: $4.7 million Upfront Cash: Undisclosed

              Deal Type: Financing March 18, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Senisca

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SENISCA Awarded Innovate UK Grant to Develop Oligonucleotide Therapeutics for The Treatment of Idiopathic Pulmonary Fibrosis (IPF).

              Details:

              The funding will be used towards the development of Oligonucleotide-based Thearpies for the treatment of idiopathic pulmonary fibrosis (IPF), using SENISCA’s proprietary technology, harnessing RNA biology to rejuvenate aged senescent cells.

              Lead Product(s): Oligonucleotide-based Thearpy

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undislcosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Innovate UK

              Deal Size: $0.7 million Upfront Cash: Undisclosed

              Deal Type: Funding April 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY